EQUIVALENCE EVALUATION OF MOISTURIZERS IN AD PATIENTS 303 (4) T. Harada, Clinical evaluation of liposome suspension on xerotic dermatoses, Hifu, 36, 697–706 (1994). (5) M. Mezei and V. Gulasekharam, Liposome—A selective drug delivery system for the topical route of administration. Lotion dosage form, Life Sci., 26, 1473–1477 (1980). (6) M. Ghyczy and V. Vacata, “Phosphatidylcholine and skin hydration,” in Skin Moisturization, J. J. Leyden and A. V. Rawlings. Eds. (Marcel Dekker, New York, NY, 2002) pp. 303–321. (7) C. C. Long and A. Y. Finlay, The fi nger-tip unit—A new practical measure, Clin. Exp. Dermatol., 16, 444–447 (1991). (8) K. Matsumoto, K. Mizukoshi, M. Oyobikawa, H. Ohshima, Y. Sakai, and H. Tagami, Objective evalu- ation of the effi cacy of daily topical applications of cosmetics bases using the hairless mouse model of atopic dermatitis, Skin Res. Technol., 11, 209–217 (2005). (9) K. Kikuchi, H. Tagami, and the Japanese Cosmetic Scientist Task Force for Skin Care of Atopic Dermatitis, Noninvasive biophysical assessments of the effi cacy of a moisturizing cosmetic cream base for patients with atopic dermatitis during different seasons, Br. J. Dermatol., 158, 969–978 (2008). (10) E. L. Simpson, T. M. Berry, P. A. Brown, and J. M. Hanifi n, A pilot study of emollient therapy for the primary prevention of atopic dermatitis, J. Am. Acad. Dermatol., 63, 587–593 (2010). (11) K. Horimukai, K. Morita, M. Narita, M. Kondo, H. Kitazawa, M. Nozaki, Y. Shigematsu, K. Yoshida, H. Niizeki, K. Motomura, H. Sago, T. Takimoto, E. Inoue, N. Kamemura, H. Kido, J. Hisatsune, M. Sugai, H. Murota, I. Katayama, T. Sasaki, M. Amagai, H. Morita, A. Matsuda, K. Matsumoto, H. Saito, and Y. Ohya, Application of moisturizer to neonates prevents development of atopic dermatitis, J. Allergy Clin. Immunol., 134, 824–830 (2014).